Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

403
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
403
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

484
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
484
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

1.3K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
1.3K
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

518
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
518
Sedatives and Hypnotics Drugs: Barbiturates01:20

Sedatives and Hypnotics Drugs: Barbiturates

511
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A...
511
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

697
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
697

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Centered Prescription Opioid Tapering Methods : A Randomized Clinical Trial.

Annals of internal medicine·2026
Same author

Off-Label Initiation of Gabapentin and Valproic Acid Among Long-Stay Nursing Home Residents With and Without Dementia.

Journal of the American Geriatrics Society·2026
Same author

Educating for the end: A decade of death literacy interventions in U.S. health professions training.

Death studies·2026
Same author

ASAM Consensus Standards for Substance Use Disorder Care Capabilities in Hospitals and Emergency Departments.

Journal of addiction medicine·2026
Same author

Benzodiazepine Tapering: Evidence Limitations and Research Recommendations.

Journal of addiction medicine·2026
Same author

Responsiveness of the 2024-2030 ACMT Research Agenda to New Funding Priorities and Research Environment.

Journal of medical toxicology : official journal of the American College of Medical Toxicology·2026

Related Experiment Video

Updated: Sep 19, 2025

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.2K

Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits.

Emily Brunner1, Chwen-Yuen A Chen2, Tracy Klein3

  • 1Hazelden Betty Ford Foundation, Minneapolis, MN, USA.

Journal of General Internal Medicine
|June 17, 2025
PubMed
Summary

This guideline offers evidence-based strategies for tapering benzodiazepine (BZD) medications. It emphasizes individualized patient care, shared decision-making, and avoiding abrupt discontinuation to manage withdrawal risks safely.

Keywords:
Benzodiazepine taperingClinical guidelineShared decision-making

More Related Videos

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K

Related Experiment Videos

Last Updated: Sep 19, 2025

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
04:34

Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia

Published on: February 17, 2023

1.2K
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.0K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.6K

Area of Science:

  • Addiction Medicine
  • Clinical Pharmacology

Background:

  • Benzodiazepine (BZD) medications are widely prescribed.
  • Concerns exist regarding long-term use and safe discontinuation.
  • A need for standardized, evidence-based tapering guidance is recognized.

Purpose of the Study:

  • To provide clinical guidance on evidence-based strategies for tapering benzodiazepine (BZD) medications.
  • To support clinicians across diverse healthcare settings and patient populations.
  • To promote safe and effective BZD discontinuation practices.

Main Methods:

  • Developed by the American Society of Addiction Medicine (ASAM) in collaboration with nine other medical societies.
  • Utilized a modified GRADE methodology and a clinical consensus process.
  • Incorporated a systematic literature review, supplemental searches, and external stakeholder review.

Main Results:

  • Guidance emphasizes ongoing risk-benefit assessment of BZD use and tapering.
  • Shared decision-making with patients is crucial for managing BZD tapering.
  • Abrupt BZD discontinuation should be avoided in physically dependent patients at risk of withdrawal.

Conclusions:

  • Tapering strategies must be individualized and adjusted based on patient response.
  • Adjunctive psychosocial interventions should be offered to support successful BZD tapering.
  • This guideline promotes a patient-centered approach to benzodiazepine management.